A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer. (MB-6)
The Purpose of This Study is to Evaluate the Effectiveness of MB-6 as Adjuvant Therapy in Reducing Neutropenia When Given Oxaliplatin-based Chemotherapy in Patients With Stage 3 Colorectal Cancer Previously Treated With Surgery.
Sponsor: Microbio Co Ltd
A observational or N/A phase clinical study on Neutropenia and Stage III Colorectal Cancer, this trial is ongoing. The trial is conducted by Microbio Co Ltd and has accumulated 9 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Recruiting
Status: Unknown Status → Recruiting
-
Apr 2020 — Jan 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jun 2018 — Apr 2020 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Recruiting NA
Phase: PHASE3 → NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Microbio Co Ltd
For direct contact, visit the study record on ClinicalTrials.gov .